Literature DB >> 1730519

Elevated p53 RNA expression correlates with incomplete osteogenic differentiation of radiation-induced murine osteosarcomas.

P G Strauss1, K Mitreiter, H Zitzelsberger, A Luz, J Schmidt, V Erfle, H Höfler.   

Abstract

An important role for the p53 gene in osteogenic sarcomas has been imputed by identification of somatically acquired gene alterations in human osteosarcomas and by the development of osteosarcomas in p53 transgenic mice. To study the involvement of p53 in radiation-induced osteosarcomagenesis, we have investigated gene alterations and expression of p53 in radiation-induced murine osteosarcomas and tumor-derived cell lines. Eighteen of 31 tumors and 8 of 9 cells lines showed alterations in the p53 gene region, or elevated levels of p53 RNA. Expression of the osteoblast marker gene bone gla protein was substantially reduced in tumors which simultaneously showed high steady-state levels of p53 RNA. Our data indicate that p53, in addition to its function in regulating DNA synthesis, may be involved in the control of osteogenic differentiation in osteosarcomagenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730519     DOI: 10.1002/ijc.2910500215

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Osteosarcomagenic doses of radium (224Ra) and infectious endogenous retroviruses enhance proliferation and osteogenic differentiation of skeletal tissue differentiating in vitro.

Authors:  J Schmidt; K Heermeier; U Linzner; A Luz; M Silbermann; E Livne; V Erfle
Journal:  Radiat Environ Biophys       Date:  1994       Impact factor: 1.925

Review 2.  Oxygen radicals and asbestos carcinogenesis.

Authors:  V D Moyer; C A Cistulli; C A Vaslet; A B Kane
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

3.  Osteoblasts are target cells for transformation in c-fos transgenic mice.

Authors:  A E Grigoriadis; K Schellander; Z Q Wang; E F Wagner
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.